Greenway Cannabis Q1 Report: Volume Growth Without Margin Recovery

Greenway Greenhouse Cannabis sold a record 2.33 million grams of cannabis in its first quarter of fiscal 2027 — revenue jumped 38% — and managed to turn positive on operating cash flow for the first time in over a year. On the surface, the quarter looks like a turnaround. Read the numbers closer and you'll find the company growing volume while selling product at a steep discount, with gross margins still too thin to matter at this scale. The question is not whether Greenway can produce more. The question is whether more production at these prices ever becomes profitable on a real basis.

Here is the quarter, in Canadian dollars, in full: net revenue of $2.23 million, up from $1.62 million a year earlier. Record grams sold. Cash cost per gram fell 30% year over year to $0.69. Average selling price across all product: $0.96 per gram. Gross margin: 12%. Net loss: $660,000. Adjusted EBITDA: $47,900. The company describes that as "positive" — which it is, technically, by $47,900 across a quarter.

The margin math is what matters. You earn $0.96 per gram on average and it costs you $0.69 in cash to produce and sell it. That spread — $0.27 per gram — is the engine. Apply it to the full 2.33 million grams and you get roughly $629,000 in gross contribution before operating expenses, fair value adjustments, and overhead. The company reports $263,000 in gross profit because inventory accounting and fair value charges eat the rest. But even the raw $0.27 spread is dangerously thin. Operating expenses for the quarter were $633,000, which wipes out the gross contribution before you even touch depreciation, interest, or the share issuances that fund the gap.

Here is what is pulling the price down: Greenway is clearing legacy inventory — older cultivars it no longer produces — at discounted prices. Management's own disclosure separates this out: excluding written-down legacy inventory, the average selling price was $1.30 per gram against that $0.69 cash cost, a $0.61 spread instead of $0.27. The core product mix, stripped of the clearance pricing, is actually running at a respectable margin. The problem is the clearance pricing is part of the quarter, and it will drag on the blended price as long as that old inventory sits in the warehouse.

The cash cost improvement is the genuine positive. A 30% drop in cost per gram, from roughly $0.99 last year to $0.69 now, means the cultivation operation is getting more efficient. Greenway operates out of a greenhouse facility in Leamington, Ontario — 167,000 square feet of growing space inside a larger produce greenhouse — and the scale is starting to show up in unit costs. That is not trivial. In an industry where wholesale pricing has been under pressure for years, cost reduction is the only lever a mid-tier cultivator controls.

But cost reduction does not solve the fundamental problem if volume growth only comes from dumping old product cheaply. Full fiscal year 2026 — the year ending March 31, 2026 — tells the harder story. Revenue declined 17% to $7.4 million. Gross profit fell 35% to $1.1 million. The company reported a $2.6 million net loss, driven by a $1.07 million inventory write-down in the fourth quarter. The write-down was on that same legacy inventory, marked to its realizable value. Adjusted EBITDA for the full year was $1.1 million — positive, but down from $1.2 million in fiscal 2025. The company has been "profitable" on an adjusted basis for two years, but the absolute dollar amount is shrinking while the underlying net loss widens.

The valuation context matters here because this is not a company with institutional investor coverage or analyst price targets. Greenway trades on the Canadian Securities Exchange under GWAY and on the OTCQB as GWAYF, with a market cap around $36 million Canadian and a share price near $0.09. The stock is down roughly 50% over the past year, with a 52-week range of $0.09 to $0.24. This is penny-stock territory, and the liquidity and shareholder-base implications flow from that: limited float, episodic trading, and a share count that expands whenever the company needs capital.

Which it does. Greenway ended the quarter with $1.13 million in cash. Quarterly operating expenses of $633,000 plus the cash cost of goods of roughly $1.6 million in a normal quarter means the burn rate exceeds $2 million per quarter before revenue recovers the gap. The $1.13 million cash position covers well under a quarter of runway, even with the improved operating cash flow of $36,778 this quarter. The working capital balance of $4.5 million sounds larger but includes receivables and inventory at cost — not all of it liquid. The company also issued 478,404 shares to a corporate finance consultant during the quarter at prices between $0.15 and $0.18, which is meaningful dilution on a stock trading at $0.09. The shares were issued above market, which at least suggests the consultant accepted some paper risk, but the dilution trajectory is the persistent headwind for every existing shareholder.

So what does the Q1 factor stack say?

Revenue growth is real — 38% year over year is not noise. Volume is expanding, cost per gram is falling, and the operating cash flow turned positive after burning nearly $900,000 in the same quarter last year. On a pure growth-and-efficiency lens, the quarter is improving. But the margin profile, the share count, and the cash runway are the three variables that keep the picture from turning into a thesis.

The international expansion angle — approximately 50% of flower sales in the prior fourth quarter were export-bound — is the one vector that could meaningfully shift the ASP. Export markets carry higher prices and are exempt from Canada's federal cannabis excise tax. If the company can grow export volume at ASPs closer to that $1.30 per-gram baseline and above, the margin story changes. If exports plateau and domestic Canadian pricing stays where it is, the company grows volume and burns cash in a loop.

For an investor evaluating this name, the question is not whether the quarter is positive. It is whether the business model reaches a durable profit threshold at a reasonable valuation and with manageable dilution. The adjusted EBITDA of $47,900 for the quarter does not answer that question. It signals that the company is surviving, not that it is solving its unit economics at scale.

What to watch next: average selling price trends on a consistent-product basis, export volume as a share of total sales, and the cash burn trajectory against the share count. If ASP holds above $1.30 on new product, operating cash flow turns positive for two consecutive quarters, and the company stops issuing shares to cover advisory fees, the picture shifts. Until then, the improving efficiency metrics are real but incomplete.